Massachusetts lost biopharmaceutical jobs in 2025 for the first time in more than 20 years, according to the MassBio 2026 Industry Snapshot released on August 25. The report found total industry employment declined 3.1% to 113,503 workers, a reduction of roughly 3,600 jobs, as biotechnology companies continued to adjust after several years of reduced investment and widespread cost-cutting. Research and development experienced the largest decline, losing 2,563 positions, or 3.9%, while overall industry wages still increased 2.2% to $26.45 billion.
Despite the employment decline, the report points to signs that the state's life sciences sector is regaining momentum. Massachusetts companies attracted $3.45 billion in biopharma venture capital during the first half of 2026, a 25% increase from the same period a year earlier, accounting for about 25% of all U.S. biopharma venture funding. The report also noted eight initial public offerings by Massachusetts life sciences companies during the first half of the year, the strongest IPO activity since 2021.
MassBio President and CEO Kendalle Burlin O'Connell said investors have begun returning to early-stage biotechnology companies after a prolonged slowdown. The report highlighted renewed hiring by several large employers, including Eli Lilly, Sanofi, AbbVie and Alnylam, while the state's biomanufacturing sector added 238 jobs in 2025, reversing two consecutive years of employment declines.
Massachusetts remains one of the nation's largest biotechnology hubs, supported by leading universities, research hospitals and pharmaceutical companies. Industry leaders said the latest figures suggest employment has lagged behind improving financial conditions but expressed optimism that stronger venture funding and public offerings could support future hiring if investment trends continue.